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the great heterogeneity caused by many treatment arms made it impossible to
develop a feasible model to estimate incremental (cost-) effectiveness compared to
other treatments. CONCLUSIONS: Outcomes research of bortezomib is compli-
cated by extensive treatment variation and great patient heterogeneity in everyday
practice. Although it is possible to generate evidence on appropriate drug use to
facilitate informed decision making, much uncertainty remained regarding the
incremental (cost-) effectiveness compared to other treatments. Policymakers
should carefully consider if outcomes research could potentially lead to an accept-
able reduction in decision-making uncertainty or that other options such as finan-
cial- or outcomes based risk sharing agreements might be more appropriate to
obtain sufficient value for money.
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OBJECTIVES: Targeted therapies are hoped to deliver high-quality, effective treat-
ments that control cost growth. Companion diagnostics (CDs) –biomarker tests to
identify patients likely to benefit– are key to this potential. However, as the US’s
IOM has noted, reimbursement for CDs may not provide optimal incentives to
develop critical CDs. To illustrate, we examined the cost:benefit of CDs based on
current reimbursement levels and the clinical and economic benefit allowed by
biomarker targeting. METHODS: We identified 6 approved CD/therapeutic combi-
nations, all in oncology. Several parameters were obtained: efficacy of therapeutic
in indicated but otherwise un-targeted patients and in patients with the biomarker,
therapeutic and diagnostic costs, and prevalence of the biomarker. CD clinical
benefit was measured by the improvement in therapeutic efficacy in targeted ver-
sus untargeted patients. CD economic benefit was based on therapy cost avoided
assuming that patients in a non-screened scenario undergo 1-month trial. To com-
pare, we estimated a similar measure of the clinical cost:benefit for all oncology
therapies approved since 2000. RESULTS: Estimated net economic benefit of CDs
ranged from about $250 to $8,000. Estimated economic cost: benefit ranged from
approximately $0.05 to $0.55 per USD saved. Estimates of the clinical cost:benefit of
CDs ranged from approximately $1.50 to over $15 per one-percent improvement in
clinical efficacy. Comparison oncology therapies are reimbursed at rates that imply
an average clinical cost:benefit of about $750 per one-percent improvement in
efficacy for non-OS benefits to $2400 per one-percent improvement in OS.
CONCLUSIONS: Our calculations support the IOM statement that current reim-
bursement for CDs may not be optimal. Relative to the value placed on oncology
therapeutics, the reimbursed value CDs is a small fraction of what would be ex-
pected under value-based pricing. This has implications for the structure of the CD
industry as well as the potential for future innovations in diagnostics.
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OBJECTIVES: In various emerging markets coverage of branded drugs is centralized
using a national formulary list of covered products. Among new branded products
pricing and coverage of expensive cancer dugs has been undergoing significant
change in various emerging markets. The objective of this study was to understand
new trends in pricing and coverage of targeted cancer therapies in Russia.
METHODS: To understand the changes in coverage of targeted cancer therapies,
the 2011 and 2012 essential drugs lists for Russia were analyzed for ATC codes
L01XC, L01XE, L01XX, L04AA and L04AX. The newly covered and non-covered prod-
ucts were identified and analyzed for factors driving the change in coverage policy.
For selected analogs price change during 2011 and 2012 was analyzed to under-
stand trends in price set by the government. RESULTS: Analysis of 2011-2012 es-
sential drug lists show significant change in coverage of targeted cancer therapies.
In 2011, only 5 targeted cancer therapies were covered in the essential drug list
(Bevacizumab, Rituximab, Trastuzumab, Imatinib and Bortezomib). In 2012, an
additional 8 branded cancer drugs were added to the list, expanding the coverage of
targeted cancer therapies to 13 products. The price change trend for selected ana-
logs show some products covered at the same price while for others price was
reduced by 5-10%. For example, for one of the covered monoclonal antibodies price
did not change during 2011 and 2012, while prices for a proteasome inhibitor and a
tyrosine kinase inhibitor were lowered by 6% and 10%, respectively.
CONCLUSIONS: Analysis of pricing and coverage of targeted cancer therapies in
Russia shows expansion of access of several products.
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OBJECTIVES: Despite the convenience of oral anticancer drugs (OAD), several fac-
tors restrict the patient access to these treatments including the way the health
care payment system (HPS) reimburses OAD or hospitals services. From the French
and American (U.S) experiences, we aimed at discussing how the HPS may create
disincentives to the use of OAD. METHODS: A literature review was performed
from Medline, Health Insurance reports, law articles, roundtable discussions to
analyze economic challenges of OAD in both systems. RESULTS: French hospitals
are financed by the Health Insurance (HI) according to the nature and quantity of
medical activities. Utilization of OAD shifts medical activities from hospital to
community settings. 2 millions of intravenous (IV) chemotherapy sessions are per-
formed yearly (i.e. 700 million Euros). A 10% decrease of IV chemotherapy sessions
would induce an income loss of 70 million Euros for hospitals. The OAD also gen-
erates additional activities (therapeutic education, control of adherence/side ef-
fects ensuring a safe use) which are not considered in the payment of hospital
activities. Although OAD are fully covered by the HI, physicians may be reluctant to
prescribe OAD partly due to these economic constraints. In the U.S system, the
reimbursement of OAD was limited to those with IV equivalence covered by the
Medicare standard insurance. Since 2003, oral/IV chemotherapy parity legislation
was adopted to provide beneficiaries with an extra-coverage ($2850 covered with a
5% copay) but patients still have to support the cost of drugs before insurance
claims, and may face with heterogeneous co-payments depending on private in-
surances, preventing those with low income to be treated with OAD. A 1% point
reduction in cost-sharing would induce a 2.7% increase in OAD utilization.
CONCLUSIONS: The adaptation of drug reimbursement systems and hospital fi-
nancing are key issues to ensure equal and safe patient access to the most appro-
priate anticancer drugs.
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OBJECTIVES: By utilizing health technology assessments to inform pricing and
reimbursement decisions, payers hope to achieve prices that afford greater value
to health care systems. To determine whether this theory holds true, we aimed to
investigate the link between drug outcomes and pricing in EU5 markets both within
and between therapy areas. METHODS: An initial screen of therapy areas was
conducted to select relevant candidates for further analysis. A qualitative assess-
ment was performed using criteria including: overall budget impact, number of
high cost therapies available, number of new entrants and availability of objective
measure of health outcomes. Based on this screen, oncology and diabetes were
selected for further analysis and comparison. Ten of the most recent entrants were
selected for further analysis in each therapy area. For each product, price premium
relative to the most relevant comparator was calculated in EU5 markets, and com-
pared to incremental change in outcome measures. In oncology, overall survival,
progression free survival and time to progression were selected as outcome mea-
sures. In diabetes, HbA1c reduction, weight loss and proportion achieving HbA1c
target were utilized. RESULTS: As expected, products displaying no or low incre-
mental improvements received minimal price premiums relative to the compara-
tor. However, although improved outcomes were associated with price premiums,
the magnitude of this increase was not correlated to the degree of improvement.
Furthermore, price premiums in oncology varied to a greater extent and reached
higher levels relative to diabetes. CONCLUSIONS: This research indicates that in
EU5 markets, drug pricing has not historically been pegged to health outcomes in a
quantitative manner. With recent and forthcoming evolutions in pricing processes
in Germany and the UK, future approvals in these and other therapy areas may
display more “rational” pricing and deliver greater value to the health care systems.
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OBJECTIVES: The UK National Institute for Health and Clinical Excellence (NICE)
recommended gefitinib for use first line in locally advanced or metastatic, EGFR
mutation positive, NSCLC when supplied via the SPA scheme. This was based on
the mean duration of treatment of 8.8 months observed in the IPASS study. The
single fixed payment under the scheme is triggered at the order of the third pack
and covers a patient for their total supply of gefitinib treatment. The objective of
this study is to evaluate the length of gefitinib therapy and confirm the value
accepted by NICE. METHODS: The SPA administrative database started in Septem-
ber 2009 to collect information on packs (30 days therapy/pack) dispensed to pa-
tients. This retrospective study includes patients fulfilling NICE eligibility criteria
and with at least 12 months potential follow-up and for whom the NHS was in-
voiced. Median time to treatment cessation was estimated from a Kaplan-Meier
curve of packs supplied to patients and mean number of packs dispensed from a
parametric failure time model. RESULTS: 265 patients met the study eligibility
criteria. These patients, for whom the NHS was invoiced the single fixed payment,
received a median of 12 packs 95%CI[10,13] with a mean of 16.2 95%CI[14.1,18.6]
packs per patient. CONCLUSIONS: The results of this observational study indicate
that the average length of gefitinib therapy in UK clinical practice is at least as long
as assumed under SPA which confirms the value accepted by NICE.
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OBJECTIVES: To evaluate utilisation of drugs involved in treatment of NSCLC, its
consumption in terms of expenditures units and number of packages prescribed in
Slovakia within 2008 -2011. METHODS: Statistical analysed data were abstracted
from State Institute for Drug Control SR, studied in accordance with financial units
(€) and number of packages prescribed every year. RESULTS: ATC L01 – antineo-
plastic agents is the one most prescribed out off all anticancer drugs (593 067
packages prescribed in 2011, 105 786 256,10 €). From L01XA platinum cytostatics –
cisplatina is the one most prescribed, with decreasing tendency in financial expen-
ditures spent (45 965 pcgs, 344 601,70 € in 2008 and 56 584 pcgs, 229 525,80 € in 2011)
compared to the least prescribed and most expensive oxiplatina. L01CD taxans –
paclitaxel and docetaxel has decreasing tendency in number of packages pre-
scribed and in financial expenditures. L01BC – the most prescribed fluorouracil has
decreasing tendency, the prescription of gemcitabin stagnates, utilization of kape-
citabin increases in number of packages and in financial units. L01XC monoclonal
antibodies – prescription of bevacizumab had increasing tendency until 2010 (13
405 pcgs, 11 339 764,50 € in 2008, 24 028 pcgs, 18 256 481,00 € in 2010 ), in 2011
prescription of cetuximab was higher than bevacizumab, and less money was
spent (cetuximab: 28 772 pcgs, 5 385 830,90€, bevacizumab: 22 661 pcgs, 17 045
495,70€). L01XE - inhibitors of protein kinase – erlotinib has increasing tendency in
number of packages prescribed and in financial expenditures (1 265 pcgs, 2 895
154,30 € in 2008, 2 071 pcgs, 3 687 581,00 € in 2011), tendency of gefitinib since 2010
when it entered the market is increasing, but it still did not overtook erlotinib (248
pcgs, 545 600,00 € in 2011). CONCLUSIONS: This study proved high economic bur-
den and continually rising amount of expenditures on antineoplastic agents, used
also in treatment of NSCLC.
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OBJECTIVES: To assess availability (patients’ access) to medicines for rare diseases
(Orphan Drugs; ODs) and to determine expenditures in the horizon of 7 years
(within years 2004 – 2010) in absolute figures and relative proportion related to
expenditures of all medicinal products in the Czech Republic (CR). METHODS: We
identified all OD registered until September 2011 by EMA. It was compared the year
of registration with the year of patients’ access to particular OD. Patients’ access to
ODs was defined as availability in official Czech distribution net. From the data-
bases of State Institute for Drug Control (SUKL), expenditures of particular OD
within all relevant years were calculated. RESULTS:Until September 2011, 49 out of
66 EMA registered ODs (74%) have been available. The mean duration of period
between registration year and year of availability in the Czech distribution net
(among already available ODs) was 2.27 years. This period was longer within past
years compared to recent years. The expenditures for ODs revealed an extreme
increase up to year 2007, while in recent years it has been more stable. In particular,
the expenditures (in million EUR) within years 2004 – 2010 were 0.2, 2.5, 12.8, 31.9,
51.2, 66.3 and 83.4, respectively. These expenditures represented 0.8%, 1.8%, 2.3%,
3.0% and 3.6% of total medicine expenditures within years 2006 – 2010 in CR. The
highest burden among all ODs have been represented by medicines for treatment
of Chronic Myeloid Leukemia and Renal Cell Carcinoma, those medicines repre-
sented 48.3% of all expenditures for ODs in 2010. CONCLUSIONS: It must be noted,
not all of available ODs are reimbursed on a standard basis, since some ODs have
conditional or exceptional (per particular patient) reimbursement. The current ex-
penditure for ODs in the CR is approximately 4% of total drugs expenditures, which
is comparable with other EU countries.
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OBJECTIVES: Anti-cancer drugs are often challenged on the ground that most clin-
ical trials show modest gains in terms of overall survival associated with high
acquisition costs. But in the same time, many oncologists make the point that
progress is incremental and should be assessed dynamically on a longer period. We
collected various data over a 20 year period (1990-2010) to provide a retrospective
view of the progress that has been achieved in medical terms and the amount of
public resources that has been spent through better treatments. METHODS: We
constructed two scenarios. The first one is a reconstruction of what actually hap-
pened. On a yearly basis, we follow the patients who reported to have a cancer to
Health Insurance. We computed the incident cases, the number of deaths, the
number of surviving patients and the average and total treatment costs, from the
public payer’s perspective. The second one is a “counterfactual” scenario which
differs only by the assumption that medical progress has stopped in 1990. Efficacy
and cost of medicines are maintained equal to their 1990 values on the whole
remaining period. RESULTS: In that hypothetical scenario, the public payer spares
nearly 60 billions of current Euros over the whole period, compared to the “real
scenario”, partly because of a fewer number of patients to treat, partly because of a
lower average treatment cost. But in the same time, the number of deceased pa-
tients rises by 670,000 and the number of lost years of life by 3.2 million. This means
that retrospectively the medical progress has allowed to save one additional year of
life at a marginal cost of 18,500 €. in current value for the public payer.
CONCLUSIONS: Investing in new and innovative cancer treatments was an effec-
tive and a cost-effective use of public resources in years 1990-2010.
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OBJECTIVES: To compare expenditures on orphan drugs (OD) in Canada, Europe
(EU5  Belgium, Sweden and Netherlands) and Australia in 2009. METHODS: ODs
were selected for analysis according to the following inclusion criteria: 1) approved
by the European Medicines Agency (EMA) between 2001 and 2011, 2) retained EMA
orphan designation until December 2011, 3) remained available until December
2011, 4) received Canadian marketing authorization, and 5) received a Canadian
Health Technology Assessment (HTA) recommendation between 2006 and 2011.
Utilization and total sales was retrieved from IMS MIDAS data availability. Com-
parison across countries was carried out by deriving the cost/capita (expressed in
CAN$ 2011) and total expenditures were compared to total drug budget as reported
from the Organization for Economic Cooperation and Development (OECD) 2011
report. RESULTS: Of the 18 drugs selected, data on 8 drugs were reported only. In
2009, Canadian cost/capita was among the lowest ($0.29) in the 10 countries while
the highest were in France, Italy and Germany ($0.94; $0.70 and $0.66 respectively).
Differences were noted for oncology and non-oncology drugs, namely expendi-
tures in rare cancers remained among the lowest in Canada ($0.19) while these
expenditures were highest in France, Germany and Italy ($0.76; $0.47 and $0.47
respectively). This trend appears to follow previously reported low access of oncol-
ogy drugs in Canada vs. other developed systems (13/14 countries). France, Sweden
and Italy were associated with the highest percentage of expenditures (0.50%;
0.41% and 0.40% respectively) while the lowest were observed in the UK, The Neth-
erlands and Canada (0.22%; 0.19% and 0.14% respectively). CONCLUSIONS: Canada
was among the lowest in regards to cost/capita and percentage of OD expenditure
compared to total drug expenditures in 10 countries. This is likely explained by the
higher rate of HTA negative recommendations which impacts payer’s decision.
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OBJECTIVES: Health technology appraisal (HTA) recommendations from the UK
National Institute of Health and Clinical Excellence (NICE) are intended to standar-
dise health care throughout the NHS, and hasten the uptake of new, more effective
medicines that are cost-effective. Several studies have investigated whether NICE
guidance influences UK drug uptake as intended, mostly using sales data. However,
this approach does not reveal which indication, line of therapy, nor patient sub-
group a drug has been used to treat. This study aims to avoid these limitations by
using IMS Health’s Oncology Analyzer™ as the primary data source. Oncology
AnalyzerTM contains detailed records for a representative patient sample, allow-
ing analyses to be focussed on the particular indication and treatment criteria
specified in NICE HTAs.METHODS:HTAs for breast cancer drugs appraised by NICE
from 2005 to 2008 were analysed. For each HTA, the proportion of the eligible
patient sub-group that received the recommended (or not recommended) drugs
from Q1 2005 to Q1 2009 was determined. Changes in drug uptake in the relevant
patient populations were assessed for the UK, and were also compared to uptake in
similar European countries. RESULTS: NICE produced 6 HTAs for breast cancer,
encompassing 8 drugs, during the period assessed. In 5 out of 6 cases, the publica-
tion of an HTA was followed by the recommended change in UK drug uptake.
However, when UK uptake of drugs recommended by NICE was compared to up-
take of the same drugs in four other European countries (France, Germany, Italy
and Spain), the UK ranked at the bottom of the group. CONCLUSIONS: The NICE
HTAs assessed were mostly followed by the intended changes in drug uptake,
suggesting they were implemented, at least by some PCTs. Despite this, interna-
tional comparisons of uptake for these drugs revealed that the UK performed
poorly compared to similar European countries.
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OBJECTIVES: Cancer patients receiving chemotherapy are at risk of venous throm-
boembolism (VTE). Information on anticoagulants use in these patients is lacking.
This retrospective cohort study describes the patterns of anticoagulant use in this
population using a US claims database. METHODS: The MarketScan® databases, a
nationwide database covering 30 million patients annually, were used. Adult
cancer patients receiving chemotherapy6 months following the cancer diagnosis
between 2004-2010 were included. Patients with bleeding history before chemo-
therapy were excluded. Six cancer types were assessed: lung, colorectal, pancreas,
bladder, stomach, and ovary. Anticoagulant use 2 weeks before or after chemother-
apy initiation was determined using National Drug Code or Healthcare Common
Procedure Coding Systems. Anticoagulant therapy duration was calculated as the
sum of total injections administered and total days of supply from prescriptions
dispensed within 2-weeks before/after chemotherapy initiation. RESULTS:Overall,
30% (N21,101) of the total patients (N70,822) used anticoagulants within 2 weeks
before/after chemotherapy. Of these, 34% used anticoagulants 2 weeks before only,
30% 2 weeks after only, and 36% in both periods. Users’ median age was 61 years
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